Developing effective treatments and understanding how the mechanism of the immune system have always been challenging for scientists. T cells, which are the frontline warriors in the battle against the infections, have been a major focus of research.
Novartis expands Scemblix label to first-line CML patients
Novartis’ chronic myeloid leukemia drug Scemblix will now be available to newly diagnosed patients, the FDA announced on Tuesday. Scemblix was first approved in 2021
October 30, 2024